Annual Activities Report 2011 - INCT-Inofar - UFRJ
Annual Activities Report 2011 - INCT-Inofar - UFRJ
Annual Activities Report 2011 - INCT-Inofar - UFRJ
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Annual</strong> <strong>Report</strong> <strong>2011</strong> | <strong>INCT</strong>-INOFAR<br />
29<br />
Associated Companies<br />
Presentation<br />
In Vitro Cells<br />
www.invitrocells.com.br<br />
In Vitro Cells – Toxicological Research S.A. is a technology based company located at Biominas<br />
Foundation (Belo Horizonte, MG). Its founders are professors of the Federal University of Minas Gerais<br />
(UFMG) in the fields of Toxicology and Biochemistry. The company is an <strong>INCT</strong>-INOFAR partner to<br />
conduct in vitro bioassays to test the safety and efficacy of new pharmaceutical candidates developed by<br />
the Institute.<br />
Cristalia Laboratories Chemical and Pharmaceutical Products<br />
www.2cristalia.com.br<br />
Cristalia is a pharmaceutical company associated with <strong>INCT</strong>-INOFAR, capable of supporting the stages<br />
of pharmacotechnical developing of new prototype compounds that reach this advanced stage of the<br />
chain of innovation in pharmaceuticals and medications. Under confidentiality and non-disclosure<br />
terms, Cristalia will benefit, if it wishes, from information on the current projects, by expressing an<br />
interest in absorbing the technology developed at <strong>INCT</strong>-INOFAR. So that the technology may be<br />
transferred, the Innovation Agency of <strong>UFRJ</strong> and its peer at another <strong>INCT</strong>-INOFAR research institution<br />
will negotiate directly with the interested parties, including financial backers.<br />
Royal Institute (Instituto Royal)<br />
www.institutoroyal.org.br<br />
Toxicology is a very delicate stage that might absolve or condemn forever a pharmaceutical candidate<br />
prototype. <strong>INCT</strong>-INOFAR prioritizes the studies of cytotoxicity, mutatoxicity, and genotoxicity, as well<br />
as acute toxicology, with the molecules that have proven attractive in terms of pharmacological activities<br />
as early as possible in the chain of pharmaceutical innovation. To ensure that all the preclinical toxicology<br />
stages are accredited in good laboratory practices (BPL/GLP), <strong>INCT</strong>-INOFAR has a partnership with<br />
the Royal Institute, which is a result of the merger of two toxicology laboratories housed in two different<br />
universities. The Genotox-Royal Institute, located at UFRGS, is responsible for the genetic toxicity<br />
studies, while Unitox-Royal, located at the University of Santo Amaro (UNISA-SP) is responsible for<br />
animal toxicity tests.<br />
Ciallyx Laboratories & Consultants<br />
www.ciallyx.com.br<br />
Ciallyx Laboratories & Consultants is a company housed at CIETEC (Incubator Center for Technological<br />
Companies) that carries out efficacy studies (concept tests) and safety studies (studies and toxicological<br />
assays) for new molecules, medications, and formulations. Ciallyx achieves results by following national<br />
and international protocols under strict quality parameters, guided by the international guidelines of<br />
the Good Laboratory Practices – GLP. The company is an <strong>INCT</strong>-INOFAR partner to conduct in vivo<br />
bioassays to evaluate the safety and efficacy of new pharmaceutical candidates developed by the Institute.
Change language